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Summary The possibility of screening the general population for prostate cancer using serum prostate-specific
antigen (PSA) level (alone or in combination with other tests) as screening test has recently been discussed. A
number of studies are on the way, but the published reports have almost exclusively been based on men
volunteering for screening. We assessed the feasibility of a screening study based on men identified from a central
population registry. A random sample of 600 men in the age groups 55, 60 and 65 years was identified from the
Finnish Population Registry as the study population. Half of them were randomised to the intervention group
and an invitation to participate was sent to them. The participation rate was 77% (230 out of 300). Twenty-five
men had a serum PSA concentration of 4.0 pgI- or above and were invited for further examination including
digital rectal examination, transrectal ultrasound and transrectal Tru-cut biopsies (directed and/or random). Six cases
ofcancer were detected among the 230 participating men, which corresponds to a detection rate of2.6% and a positive
predictive value of 24%. The number of cases detected is equivalent to the expected number of prostate cancer cases
during a 10 year follow-up in this population. The ratio of free to total PSA was also measured and a cut-off level of
0.20 was chosen. Its use as an additional criterion ofthe screening test would have decreased the prevalence offalse-
positive screening tests from 8% (19 of230) to 3% (7 of230) at a cost ofmissing one ofthe six cancers compared with
serum total PSA concentration alone. Ofthe six cancers, five were clinically regarded as localised and locally confined
disease was confirmed pathologically in four of them. In conclusion, a population-based study in Finland seems
feasible and the properties of the PSA test can be regarded as suitable for a randomised screening study. Thus, all
prerequisites for a multicentre study, which is planned, seem to exist.
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In recent years, the possibility of screening for prostatic
carcinoma using measurement of serum prostate-specific
antigen (PSA) concentration as the screening test has been
subject to increasing interest.
The general prerequisites of screening for disease are: (1)
the disease should have public health importance, i.e. it
should be common and its health consequences significant;
(2) the disease should have an early stage, during which it is
detectable and the treatment results are more favourable
compared with detection through normal clinical practice; (3)
a screening test should be available with adequate sensitivity,
specificity, as well as positive and negative predictive value;
(4) the screening test should be acceptable to the target
population and the cost and negative effects ofthe test should
be in balance with the potential benefit from screening
(modified from Wilson and Jungner, 1969).
Prostate cancer is the second most common cancer among
men in most industrialised countries with age-adjusted (to the
world standard population) incidence rate approximately
50-100 per 100 000 person-years (Coleman et al., 1993).
The incidence rates are increasing 10-20% per five calendar
years (Coleman et al., 1993). Mortality varies between 10 and
20 per 100 000 person-years with little or no increasing
trend (Coleman et al., 1993). Thus, it clearly fulfils the first
criterion of public health importance.
Radical treatment of early prostate cancer often leads to
complete cure from the disease, which cannot be achieved in
extracapsular disease (Walsh et al., 1994; Zagars et al., 1995).
Increased detection of organ-confined prostate cancer is
possible by PSA-based screening (Catalona et al., 1993;
Mettlin et al., 1993a). Thus, the second criterion may also be
fulfilled. This is on the condition that localised cancer implies
early detection and that the favourable survival is not only
due to lead time and lower aggressiveness of localised
cancers. This potential fallacy can be assessed only by using
mortality as the main endpoint.
Non-randomised studies of men volunteering for preva-
lence screening have shown sensitivity of 72% and specificity
of 91% for the PSA test with a cut-off level of 4.0 pg 1-'
(Labrie et al., 1992). The corresponding positive predictive
value has been 29-33% (Labrie et al., 1992; Brawer et al.,
1993; Catalona et al., 1993; Mettlin et al., 1993b). Thus, the
PSA test may also satisfy the third criterion regarding
validity of the screening test. The diagnostic accuracy may
be further improved by simultaneous use of other examina-
tions such as digital rectal examination (DRE).
So far, no results on participation rate in population-
based, randomised studies have been published. Thus, it has
not been possible to evaluate the fourth criterion, accept-
ability of the screening test.
The aim of our study was to assess the feasibility of a
population-based prostatic cancer screening study based on
PSA, i.e. acceptability to the target population and
performance of the screening test. For this purpose, we
estimated the participation rate, proportion of screening
positive findings, positive predictive value and detection rate
on a random sample of men identified from a central
population registry.
Material and methods
A random sample of 600 men aged 55, 60 and 65 years (200
men in each age group) residing in the city of Tampere, or
the neighbouring municipalities, was identified from the
Finnish Population Registry. The information obtained
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1996included name, personal identification number and address.
The study was accepted by the ethics committee of Tampere
University Hospital. Three men were excluded from the study
because of prevalent prostate cancer. The study population
was randomised into two groups: half of the men formed the
intervention group and were invited to participate in the
study, and half were assigned to the control group and were
not contacted. After randomisation, an invitation to
participate was sent by mail to the men in the intervention
group with an attached information package about prostate
cancer (incidence, risk factors, prognosis, treatment options).
It was not thought necessary to offer an alternative
intervention to the control group, because the efficacy of PSA
screening (or any alternative method of screening for
prostatic cancer) has not been demonstrated. Because no
intervention was directed to the control group, it was not
necessary to contact them.
After obtaining informed consent for participation, 15 ml
of blood was drawn in a vacutainer tube with heparin from
each participant at the Pirkanmaa Cancer Society Clinic. The
information sent by mail was also given in person before
drawing the blood sample. Blood sampling was conducted in
April-May 1994.
The serum PSA determinations were performed at the
Clinical Laboratory of the Department of Gynaecology and
Obstetrics, Helsinki University Central Hospital. For total
PSA, the Delfia kit (Wallac, Turku, Finland) based on time-
resolved immunofluorometry was used (Stenman et al., 1990).
For determination of free to total PSA, free and total PSA
were determined by immunofluorometric assay (IFMA).
Monoclonal antibody (MAb) HI 17 (Abbott, North Chicago,
IL, USA) was used as a solid phase MAb in the IFMAs for
free PSA and total PSA. MAb 5A10 was used as a tracer in
the free PSA assay and MAb H50 (Abbott, North Chicago,
IL, USA) in the total PSA assay (Leinonen et al., 1996).
Men with serum PSA concentration >4.0 pg 1' were
referred to the Division of Urology, Tampere University
Hospital. Urological examination of the screening-positive
men was conducted, including a DRE and transrectal
ultrasound (TRUS) of the prostate. TRUS was performed
using a Briiel-Kjaer 1846 ultrasound scanner and a 7 MHz
transducer (type 8551). Six random transrectal Tru-cut
biopsies of the prostate were performed on all men with
PSA>4.0 p,g 1-', supplemented by a directed biopsy if a
suspicious focus was detected by DRE, TRUS or both.
Men in the control group were followed up for cancer
incidence using a record linkage with the nationwide,
population-based Finnish Cancer Registry, which has an
almost complete coverage of cancer cases diagnosed in
Finland (Teppo et al., 1994).
Results
Ofthe 300 men invited, 230 participated (77%) (Table I). The
serum PSA concentration was below 2.0 pg 1-l in 180 men
(78%), between 2.0 and 3.9 pg l-l in 25 men and 4.0 pg I-'
or above in 25 men. The percentage of men with PSA
between 2.0 and 4.0 pg 1-' increased with age (Figure 1). A
similar tendency was observed for PSA levels of 4.0 pg I-'
and above, although not as clearly.
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All 25 men with PSA of 4.0 pg 1-1 or above were referred
for urological examination. Among them, ten had a DRE
finding indicative ofcancer. A hypoechoic lesion was detected
in TRUS for one of the 22 examined men (two men were not
examined because of a broken machine). One of the men with
elevated PSA went to a private urologist and no cancer was
diagnosed, but information on DRE and TRUS findings are
not available. Six cases of prostatic carcinoma were detected.
This corresponds to positive predictive value of 24%. Other
diagnoses were prostatic hyperplasia (n = 13), normal tissue
(n =2), metaplasia or atypical hyperplasia (n =2), prostatitis
(n = 1) and prostatic intraepithelial neoplasia (n = 1). Of the
men with cancer, four had a PSA concentration between 4.0
and 10.0 pg I-', and two above 20 pg 1` (Figure 1).
Based on age-specific incidence rates in Finland, it was
estimated that six prostate cancers corresponded to expected
numbers of cases in a 10 year follow-up in the screened
population.
Of the six cancers, four were grade I and two were grade
II (Table II). Five cancers were clinically confined to the
prostate (one TI and four T2) and were treated by radical
prostatectomy. Pathological staging confirmed organ-con-
fined disease in four cases and revealed seminal vesicle
invasion in one of the clinically localised tumours. The exact
pathological stage for these cases were: Tlb, T2a, T2a, T2c,
T3c. One case had both local invasion and bone metastases,
(clinical stage T3 Nx Ml) and was treated with endocrine
therapy (LHRH agonist). No pathological staging was
available for this case.
All men with elevated PSA (4.0 pg 1-l or above), but
without cancer diagnosis in the initial examination, were re-
examined with DRE and biopsy at 1 year and those with
PSA 10 pg 1-' also at 6 months from the initial examination.
The follow-up has not revealed any additional prostate
cancers.
The ratio of free to total PSA (F/T PSA) was also
measured for all men. The relationship of the serum total
PSA concentration and F/T PSA is shown in Figure 2.
Among men with serum PSA concentration of 4.0 pg 1-' or
above, the use of F/T PSA as an additional criterion
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Figure 1 The serum total PSA concentration (pgI-1) by age
among men with and without prostate cancer, Finnish pilot study
of prostate cancer screening. 0, Prostate cancer; 0, no cancer.
Table I Results of the pilot PSA screening study in Finland
2KPSA PSA
Invited Participated <4 >4 Cancer PPV
Age (N) (%) (%) (%) (%) (%) pTI 2
55 100 78 8 5 2.6 50 1/2
60 100 64 7 13 1.6 13 1/1
65 100 90 17 14 3.3 23 2/3
Total 300 77 11 11 2.6 24 4/6
PPV, positive predictive value.
Table II Characteristics of the cancers detected in the Finnish pilot
study of prostate cancer screening
Case
no. Age PSA FIT PSA DRE TRUS Grade Stage
1 65 26.9 0.08 Suspect Normal I pT2cNOMO
2 65 26.0 0.07 Suspect Normal II cT3NxM1
3 55 9.6 0.06 Suspect Normal II pT3cNOMO
4 60 6.3 0.31 Suspect Normal I pTIbNOMO
5 55 5.5 0.17 Suspect Normal I pT2aNOMO
6 65 5.3 0.17 Suspect Suspect I pT2aNOMO
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Figure 2 The total serum PSA concentration (MgI- 1') by the
proportion of free to total PSA among men with and without
prostate cancer, Finnish pilot study of prostate cancer screening.
0, No cancer; 0, prostate cancer; +, not biopsied.
increased the positive predictive value of the screening test.
When the cut-off level of 0.20 for F/T PSA was used (with
decreased values indicating a high risk of prostate cancer),
the positive predictive value for the combination of the two
tests was 42%. This procedure would have resulted in a
reduction of screening positive findings by half to 12 men
(5%), i.e. a reduction in false-positive screening tests from
8% to 3%. This would have been obtained at a cost of
missing one localised prostate cancer.
No cases of prostate cancer have yet been diagnosed in the
control group or among non-participants (2 years from
randomization).
Discussion
Our study was population based, which, combined with a
high participation rate (77%), efficiently improved external
validity and reduced selection bias compared with self-
enrolment used in most other studies. Nevertheless, owing
to the small number of subjects in our feasibility study, one
should be cautious in drawing conclusions. The high
participation rate observed in our study indicates that
screening based on serum PSA concentration is feasible in
Finland and that Finnish men aged 55-65 years regard the
screening procedure as acceptable. However, we have not at
this stage approached participants and non-participants to
evaluate satisfaction and reasons for non-participation.
A relatively low cut-off level for PSA concentration was
chosen to allow assessment of higher thresholds for screening.
Four out of six men with prostate cancer had a PSA
concentration below 10 ig 1-', suggesting that most of the
cancers would be missed, at least in a single screening round,
if a higher cut-off level were to be used. We used the Delfia
kit by Wallac for determining the total PSA concentration. It
has a very good correlation with, e.g. the Hybritech Tandem-
R method (r=0.99) (Stenman et al., 1990).
The proportion of screening-positive men (11%) was
similar to that observed in other studies (Chadwick et al.,
1991; Brawer et al., 1992; Labrie et al., 1992; Catalona et al.,
1993; Mettlin et al., 1993b). This implies that PSA-based
screening requires a relatively large number of urological
examinations at a considerable cost. It may be possible to
improve the positive predictive value of the PSA test, and
thus to reduce the need for diagnostic examinations, by
determination of the free and total PSA (Stenman et al.,
1994). Other modifications to the PSA test, such as PSA
density, PSA velocity or age-referenced PSA, do not seem to
improve the performance of the screening test compared with
serum PSA concentration alone (Catalona et al., 1994;
Mettlin et al., 1994).
The positive predictive value of 24% in our study can be
considered fairly good, although it indicates that three out of
four screening-positive men are actually free of the disease.
The most important source of false-positive tests seems to be
prostatic hyperplasia. It might by improved by applying a
higher cut-off level, but this would automatically diminish
sensitivity.
These figures can be compared with those observed in
breast cancer screening. In mammography screening for
breast cancer, 4% of women have a screening positive
finding and are subject to further diagnostic examination
(Hakama et al., 1991). Breast cancer is diagnosed in 0.4% of
the screened women, which corresponds to a positive
predictive value of 10% (Hakama et al., 1991).
One must bear in mind, however, that the results are
obtained from the first screening round in a previously
unscreened population. In a prevalence screen, the yield may
be higher and the tumours less aggressive than in subsequent
screening rounds. This may also affect the performance
characteristics of the screening test, including sensitivity,
specificity and stage distribution.
In our study, sensitivity and specificity could not be
assessed because the true prevalence of disease was not
known among men with PSA below 4.0 jug 1-l. The same
applies to the negative predictive value. In the literature, a
sensitivity of 72%, specificity of 91% and negative predictive
value of 98% have been reported for a cut-off level of
4.0 jug 1I1 in a study with DRE, TRUS and PSA as
independent indications for biopsy (Labrie et al., 1992).
One of the potential problems in screening for prostate
cancer is the possibility of overdiagnosis, i.e. screening may
lead to detection of indolent lesions that may fulfil the
histological criteria of cancer, but would never surface
clinically during the subject's lifetime. The detection rate in
our study (2.6%) was similar to earlier studies, in which it
has ranged from 1% to 5% (Chadwick et al., 1991; Brawer et
al., 1992; Labrie et al., 1992; Catalona et al., 1993). However,
it was quite high relative to the life-time risk of developing a
prostate cancer. Based on the age-specific incidence rates in
Finland, the detection rate of 2.6% corresponds to the
expected number of prostate cancers within 10 years of
follow-up of the screened men (assuming constant incidence
rates at the level of 1992 for the whole of Finland). In
Finland, the life-time risk of prostate cancer between the ages
55 and 80 is approximately 9%. Comparison of this figure
with the yield of 2.6% in our study suggests that to avoid
overdiagnosis, a single screening round should reduce the life-
time risk of subsequent prostate cancer by at least 25%. The
first results suggest, however, that the detection rate in the
following screening rounds is probably 25-50% smaller
compared with the prevalence screen (Catalona et al., 1993;
Mettlin et al., 1993b). Thus, the probability of overdiagnosis
seems to decrease in the consecutive screening rounds. The
situation may be similar to that encountered in cervical
cancer screening, where all invasive in situ lesions are treated,
although only a quarter of them would develop into cancer
(Hakama and Rasanen-Virtanen, 1976).
Several case-control studies based on serum banks have
been published that enable retrospective assessment of PSA
level preceding the diagnosis of prostate cancer (Carter et al.,
1992; Helzlsouer et al., 1992; Paus et al., 1992; Stenman et
al., 1994; Gann et al., 1995; Whittemore et al., 1995). In these
studies, no screening procedures were performed apart from
drawing a blood sample for storage. Later on, the samples
were analysed from subjects with subsequent prostate cancer
and from controls. Thus, the advantage of these studies is the
lack of overdiagnosis, i.e. over-representation of lesions that
would never have developed into a symptomatic phase. The
results suggest that serum PSA has a high sensitivity up to 5
years before clinical surfacing of prostate cancer and an
elevation of PSA can be detected up to 10 years before
diagnosis. Thus, the sensitivity of the test may after all be
good and overdiagnosis avoidable.
A prerequisite for screening is detection of cases at curable
stage. In our study, five of the six cancers detected hadPSA screening in Finland
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clinically local stage and pathological staging confirmed that
the disease was confined to the prostate in four cases. This is
a more favourable stage distribution than that observed
among cases diagnosed through normal clinical practice in
the same ages (according to data from the Finnish Cancer
Registry, approximately 45% of prostate cancers in Finland
are currently diagnosed at local stage). This finding is in
accordance with previous reports (Catalona et al., 1993;
Mettlin et al., 1993a). Only one of the six tumours was small
(Tlb), suggesting that the screening-detected cancers are not
indolent, but have clinical relevance.
Our results, although based on a small sample, support
earlier results, suggesting that the combination of ratio of free
to total PSA increases the specificity and the positive
predicitive value of the screening test (Stenman et al.,
1994). The combination of the two tests, the total PSA and
the ratio of free to total PSA, has the potential to
substantially reduce the number of false-positive findings
and hence the costs and harmful side-effects of a screening
programme. However, the improved sensitivity can only be
gained with some loss of specificity. In our study, one of the
six cancers would have been missed if the screening positive
finding was defined as serum PSA concentration of 4.0 ,ug 1`
or higher and F/T PSA 0.20 or below. We find this level of
false negatives is acceptable, especially as overdiagnosis is one
of the most important concerns for prostate cancer screening.
Nevertheless, the usefulness of the F/T PSA will only be
determined with further experience as our results need to be
confirmed in larger studies. Also, more studies on the optimal
cut-off level of the F/T PSA are needed.
Evaluation of the efficacy of a screening programme
should be based on reduction of mortality from the disease,
which can be done only on the basis of large randomised
studies (Miller, 1982). In prostate cancer, the potential
reduction of prostate cancer mortality remains to be
demonstrated with long-term follow-up and it may be
small. Because of this and the facts that the treatment is
associated with high frequency of side-effects and that the
saved years of life are at an older age, assessment of quality
of life is essential for evaluation of the possible benefit and
harm caused by prostate cancer screening. Furthermore, the
cost-effectiveness of the screening programme should be
assessed. So far, no data are available regarding the effect
of prostate cancer screening on mortality from the disease,
nor on quality of life or cost-efficiency. A European
collaborative study has been set up to investigate these end
points, with Finland as a participating country (Schr6der et
al., 1995).
The results of our pilot study using a serum PSA cut-off
level of 4.0 HIg I` suggest that a high participation rate can
be achieved in the general population and that the proportion
of screening-positive men, positive predictive value and
detection rate are at an acceptable level. Thus, a popula-
tion-based randomised study on screening for prostate cancer
with prostate cancer mortality, quality of life and cost-
efficiency as end points is feasible in Finland.
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